70390-94-2

Basic information

• Product Name: 2-(chloroMethyl)-5-phenyl-1,3,4-thiadiazole
• Synonyms: 2-(chloroMethyl)-5-phenyl-1,3,4-thiadiazole;2-(chloroMethyl)-5-phenyl-1
• CAS NO: 70390-94-2
• Molecular Formula: C₉H₇ClN₂S
• Molecular Weight: 210.68328
• Mol File: 70390-94-2.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-(chloroMethyl)-5-phenyl-1,3,4-thiadiazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(chloroMethyl)-5-phenyl-1,3,4-thiadiazole(70390-94-2)
• EPA Substance Registry System: 2-(chloroMethyl)-5-phenyl-1,3,4-thiadiazole(70390-94-2)

Safety Data

• Hazardous Substances Data: 70390-94-2(Hazardous Substances Data)

Usage

General Description

2-(chloroMethyl)-5-phenyl-1,3,4-thiadiazole, also known as CMPT, is a chemical compound with the molecular formula C9H7ClN2S. It belongs to the class of thiadiazole compounds, which are known for their diverse biological and pharmacological activities. CMPT has been studied for its potential use as an antifungal and antimicrobial agent, and has shown promising activity against a range of pathogens. It is also being explored for its potential as a building block in the synthesis of new pharmaceutical compounds. Overall, CMPT is a versatile chemical with potential applications in various fields, including medicine, agriculture, and materials science.

Upstream product

• 36743-66-5 ethyl chloroacetimidate hydrochloride 
• 20605-40-7 thiobenzhydrazide 
• 33575-83-6 2-(chloromethyl)-5-phenyl-1,3,4-oxadiazole 
• 50677-24-2 Ν-p-methylbenzoyl-N'-chloroacetyl 

Downstream Products

• 70390-98-6 N-hydroxy-5-phenyl-[1,3,4]thiadiazole-2-carboximidoyl chloride 
• 1293956-51-0 2-(bis((5-phenyl-1,3,4-thiadiazol-2-yl)methylthio)methylene)malononitrile 
• 121564-79-2 2-Azidomethyl-5-phenyl-[1,3,4]thiadiazole 
• 1342816-82-3 2-cyanoethyl [(5-phenyl-1 ,3,4-thiadiazol-2-yl)methyl]dithiocarbamate 
• 85730-57-0 C-(5-Phenyl-[1,3,4]thiadiazol-2-yl)-methylamine 
• 1287305-28-5 5-(bis((5-phenyl-1,3,4-thiadiazol-2-yl)methylthio)methylene)-dihydro-2-thioxopyrimidine-4,6-(1H,5H)-dione 
• 1287305-25-2 5-(bis((5-phenyl-1,3,4-thiadiazol-2-yl)methylthio)methylene)pyrimidine-2,4,6-(1H,3H,5H)-trione 
• 70391-04-7 N-hydroxy-5-phenyl-[1,3,4]thiadiazole-2-carboximidoyl azide 
• 70391-08-1 2-phenyl-1,3,4-thiadiazole-5-carbonitrile 
• 104090-56-4 Methyl-(5-phenyl-[1,3,4]thiadiazol-2-ylmethyl)-amine 

Relevant articles and documents

Discovery of 3,5-dimethylisoxazole derivatives as novel, potent inhibitors for bromodomain and extraterminal domain (BET) family

Bromodomain and extra-terminal (BET) is a promising therapeutic target for various hematologic cancers. We used the BRD4 inhibitor compound 13 as a lead compound to develop a variety of compounds, and we introduced diverse groups into the position of the compound 13 orienting toward the ZA channel. A series of compounds (14–23, 38–41, 43, 47–49) bearing triazolopyridazine motif exhibited remarkable BRD4 protein inhibitory activities. Among them, compound 39 inhibited BRD4(BD1) protein with an IC50 of 0.003 μM was superior to lead compound 13. Meanwhile, compound 39 possess activity, IC50 = 2.1 μM, in antiproliferation activity against U266 cancer cells. On the other hand, compound 39 could arrest tumor cells into the G0/G1 phase and induce apoptosis, which was consistent with its results in inhibiting cell proliferation. Biological and biochemical data suggest that BRD4 protein might be a therapeutic target and that compound 39 is an excellent lead compound for further development.

Biphenyl heterocyclic derivatives, their preparation and their use as medicaments (by machine translation)

The present invention relates to a novel biphenyl heterocyclic derivative represented by a general formula (I) and a preparation method thereof and use of a pharmaceutical composition containing the derivative for preparation of a drug for treating diabetes. The biphenyl heterocyclic derivative has extremely excellent hypoglycemic activity in vivo, and excellent in vivo safety and low liver toxicity risk of the compound having such a structure are unexpectedly found, and the novel biphenyl heterocyclic derivative may be used for preventing or treating diabetes.

Discovery of novel heteroarylmethylcarbamodithioates as potent anticancer agents: Synthesis, structure-activity relationship analysis and biological evaluation

A series of new analogs based on the structure of lead compound 10 were designed, synthesized and evaluated for their in vitro anti-cancer activities against four selected human cancer cell lines (HL-60, Bel-7402, SK-BR-3 and MDA-MB-468). Several synthesized compounds exhibited improved anti-cancer activities comparing with lead compound 10. Among them, 1,3,4-oxadiazole analogs 17o showed highest bioactivity with IC50 values of 1.23, 0.58 and 4.29 μM against Bel-7402, SK-BR-3 and MDA-MB-468 cells, respectively. It is noteworthy that 17o has potent anti-proliferation activity toward a panel of cancer cells with relatively less cytotoxicity to nonmalignant cells. The further mechanistic study showed that it induced apoptosis and cell cycle arrest through disrupting spindle assembly in mitotic progression, indicating these synthesized dithiocarbamates represented a novel series of anti-cancer compounds targeting mitosis.